The role of B cell-activating factor in autoimmune myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 1274, Issue 1, 2012, Pages 60-67

  Lisak, Robert P ^a   Ragheb, Samia ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; B cells; BAFF; Cytokines; Immunotherapy

Indexed keywords

ANTIBODY; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN; MUSK ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; HUMAN; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; UPREGULATION;

EID: 84871309497     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06842.x     Document Type: Article

References (123)

1. Appel, S.H., R.R. Almon & N. Levy. 1975. Acetylcholine receptor antibodies in myasthenia gravis. N. Engl. J. Med. 293: 760-761.
2. Lindstrom, J.M., M.E. Seybold, V.A. Lennon, et al. 1976. Antibody to acetylcholine receptor in myasthenia gravis. prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054-1059.
3. Ragheb, S. & R. Lisak. 1994. The immunopathogenesis of acquired (autoimmune) myasthenia gravis. In Handbook of Myasthenia Gravis and Myasthenic Syndromes. R. Lisak, Ed.: 239-276. New York. Marcel Dekker.
4. McConville, J., M.E. Farrugia, D. Beeson, et al. 2004. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 55: 580-584.
5. Evoli, A., P.A. Tonali, L. Padua, et al. 2003. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126: 2304-2311.
6. Oh, S.J., Y. Hatanaka, S. Hemmi, et al. 2006. Repetitive nerve stimulation of facial muscles in musk antibody-positive myasthenia gravis. Muscle Nerve 33: 500-504.
7. Sanders, D.B., K. El-Salem, J.M. Massey, et al. 2003. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60: 1978-1980.
8. Higuchi, O., J. Hamuro, M. Motomura & Y. Yamanashi. 2011. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. 69: 418-422.
9. Pevzner, A., B. Schoser, K. Peters, et al. 2012. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J. Neurol. 259: 427-435.
10. Zhang, B., J.S. Tzartos, M. Belimezi, et al. 2012. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch. Neurol. 69: 445-451.
11. Vincent, A., G.K. Scadding, H.C. Thomas & J. Newsom-Davis. 1978. In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet 1: 305-307.
12. Scadding, G.K., A. Vincent, J. Newsom-Davis & K. Henry. 1981. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 31: 935-943.
13. Fujii, Y., Y. Monden, J. Hashimoto, et al. 1985. Acetylcholine receptor antibody-producing cells in thymus and lymph nodes in myasthenia gravis. Clin. Immunol. Immunopathol. 34: 141-146.
14. Lisak, R.P., A.I. Levinson, B. Zweiman & M.J. Kornstein. 1986. Antibodies to acetylcholine receptor and tetanus toxoid: in vitro synthesis by thymic lymphocytes. J. Immunol. 137: 1221-1225.
15. Lisak, R.P., C. Laramore, B. Zweiman & A. Moskovitz. 1983. In vitro synthesis of antibodies to acetylcholine receptor by peripheral blood mononuclear cells of patients with myasthenia gravis. Neurology 33: 604-608.
16. Lisak, R.P., C. Laramore, A.I. Levinson, et al. 1986. Suppressor T cells in myasthenia gravis and antibodies to acetylcholine receptor. Ann. Neurol. 19: 87-89.
17. Lisak, R.P., C. Laramore, A.I. Levinson, et al. 1984. In vitro synthesis of antibodies to acetylcholine receptor by peripheral blood cells: role of suppressor T cells in normal subjects. Neurology 34: 802-805.
18. Lisak, R.P., A.I. Levinson, B. Zweiman & M.J. Kornstein. 1987. In vitro synthesis of IgG and antibodies to AChR by peripheral and thymic lymphocytes. Ann. N.Y. Acad. Sci. 505: 39-49.
19. Levinson, A.I., A. Dziarski, R.P. Lisak, et al. 1981. Comparative immunoglobulin synthesis by blood lymphocytes of myasthenics and normals. Ann. N.Y. Acad. Sci. 377: 385-392.
20. Levinson, A.I., A. Dziarski, R.P. Lisak, et al. 1981. Polyclonal B-cell activity in myasthenia gravis. Neurology 31: 1198-1201.
21. Levinson, A.I., R.P. Lisak, B. Zweiman & M. Kornstein. 1985. Phenotypic and functional analysis of lymphocytes in myasthenia gravis. Springer Semin. Immunopathol. 8: 209-233.
22. Levinson, A.I., B. Zweiman, R.P. Lisak, et al. 1984. Thymic B-cell activation in myasthenia gravis. Neurology 34: 462-468.
23. Levinson, A.I., B. Zweiman & R.P. Lisak. 1990. Pokeweed mitogen-induced immunoglobulin secretory responses of thymic B cells in myasthenia gravis: selective secretion of IgG versus IgM cannot be explained by helper functions of thymic T cells. Clin. Immunol. Immunopathol. 57: 211-217.
24. Zweiman, B., A.I. Levinson & R.P. Lisak. 1989. Phenotypic characteristics of thymic B lymphocytes in myasthenia gravis. J. Clin. Immunol. 9: 242-247.
25. Simpson, J.A. 1977. Myasthenia gravis-validation of a hypothesis. Scott. Med. J. 22: 201-210.
26. Simpson, J.A. 1966. Myasthenia gravis as an autoimmune disease: clinical aspects. Ann. N. Y. Acad. Sci. 135: 506-516.
27. Simpson, J.F., M.R. Westerberg & K.R. Magee. 1966. Myasthenia gravis. An analysis of 295 cases. Acta. Neurol. Scand. 42(Suppl 23): 1-7.
28. Moore, P.A., O. Belvedere, A. Orr, et al. 1999. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260-263.
29. Schneider, P., F. MacKay, V. Steiner, et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189: 1747-1756.
30. Mackay, F., P.A. Silveira & R. Brink. 2007. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr. Opin. Immunol. 19: 327-336.
31. Ragheb, S. & R.P. Lisak. 2011. B-cell-activating factor and autoimmune myasthenia gravis. Autoimmune Dis. 2011: 939520.
32. Nardelli, B., O. Belvedere, V. Roschke, et al. 2001. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97: 198-204.
33. Craxton, A., D. Magaletti, E.J. Ryan & E.A. Clark. 2003. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 101: 4464-4471.
34. Krumbholz, M., D. Theil, T. Derfuss, et al. 2005. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201: 195-200.
35. Serafini, B., M. Severa, S. Columba-Cabezas, et al. 2010. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J. Neuropathol. Exp. Neurol. 69: 677-693.
36. Magliozzi, R., S. Columba-Cabezas, B. Serafini & F. Aloisi. 2004. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148: 11-23.
37. Chu, V.T., P. Enghard, S. Schurer, et al. 2009. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum. 60: 2083-2093.
38. Xiao, B.G., R.S. Duan, H. Link & Y.M. Huang. 2003. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Cell Immunol. 223: 63-69.
39. Mackay, F., P. Schneider, P. Rennert & J. Browning. 2003. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21: 231-264.
40. Kalled, S.L., C. Ambrose & Y.M. Hsu. 2005. The biochemistry and biology of BAFF, APRIL and their receptors. Curr. Dir. Autoimmun. 8: 206-242.
41. Bjartmar, C., R.P. Kinkel, G. Kidd, et al. 2001. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57: 1248-1252.
42. Schiemann, B., J.L. Gommerman, K. Vora, et al. 2001. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293: 2111-2114.
43. Mackay, F., S.A. Woodcock, P. Lawton, et al. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190: 1697-1710.
44. Khare, S.D., I. Sarosi, X.Z. Xia, et al. 2000. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. USA 97: 3370-3375.
45. O'Connor, B.P., V.S. Raman, L.D. Erickson, et al. 2004. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199: 91-98.
46. Benson, M.J., S.R. Dillon, E. Castigli, et al. 2008. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180: 3655-3659.
47. Lesley, R., Y. Xu, S.L. Kalled, et al. 2004. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20: 441-453.
48. Thien, M., T.G. Phan, S. Gardam, et al. 2004. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20: 785-798.
49. Ng, L.G., A.P. Sutherland, R. Newton, et al. 2004. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol. 173: 807-817.
50. Bossen, C. & P. Schneider. 2006. BAFF, APRIL and their receptors: structure, function and signaling. Semin. Immunol. 18: 263-275.
51. Mackay, F. & P. Schneider. 2009. Cracking the BAFF code. Nat. Rev. Immunol. 9: 491-502.
52. von Bulow, G.U., J.M. van Deursen & R.J. Bram. 2001. Regulation of the T-independent humoral response by TACI. Immunity 14: 573-582.
53. Yan, M., H. Wang, B. Chan, et al. 2001. Activation and accumulation of B cells in TACI-deficient mice. Nat. Immunol. 2: 638-643.
54. Seshasayee, D., P. Valdez, M. Yan, et al. 2003. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18: 279-288.
55. Castigli, E., S.A. Wilson, L. Garibyan, et al. 2005. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat. Genet. 37: 829-834.
56. Salzer, U., H.M. Chapel, A.D. Webster, et al. 2005. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat. Genet. 37: 820-828.
57. Sakurai, D., Y. Kanno, H. Hase, et al. 2007. TACI attenuates antibody production costimulated by BAFF-R and CD40. Eur. J. Immunol. 37: 110-118.
58. Miller, D.J. & C.E. Hayes. 1991. Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice. Eur. J. Immunol. 21: 1123-1130.
59. Harless, S.M., V.M. Lentz, A.P. Sah, et al. 2001. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr. Biol. 11: 1986-1989.
60. Yan, M., J.R. Brady, B. Chan, et al. 2001. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol. 11: 1547-1552.
61. Sasaki, Y., S. Casola, J.L. Kutok, et al. 2004. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J. Immunol. 173: 2245-2252.
62. Shulga-Morskaya, S., M. Dobles, M.E. Walsh, et al. 2004. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J. Immunol. 173: 2331-2341.
63. Xu, S. & K.P. Lam. 2001. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol. Cell Biol. 21: 4067-4074.
64. Groom, J., S.L. Kalled, A.H. Cutler, et al. 2002. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 109: 59-68.
65. Mariette, X., S. Roux, J. Zhang, et al. 2003. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann. Rheum. Dis. 62: 168-171.
66. Krumbholz, M., U. Specks, M. Wick, et al. 2005. BAFF is elevated in serum of patients with Wegener's granulomatosis. J. Autoimmun. 25: 298-302.
67. Bosello, S., P. Youinou, C. Daridon, et al. 2008. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J. Rheumatol. 35: 1256-1264.
68. Fuhlhuber, V., S. Bick, A. Kirsten, et al. 2009. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J. Neuroimmunol. 210: 87-91.
69. Okada, K., T. Matsushita, J. Kira & S. Tsuji. 2010. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology 74: 177-178.
70. Vadacca, M., D. Margiotta, D. Sambataro, et al. 2010. BAFF/APRIL pathway in Sjogren syndrome and systemic lupus erythematosus: relationship with chronic inflammation and disease activity. Reumatismo 62: 259-265.
71. Vannucchi, G., D. Covelli, N. Curro, et al. 2012. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy. J. Clin. Endocrinol. Metab. 97: E755-E759.
72. Ragheb, S., Y. Li, K. Simon, et al. 2011. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult. Scler. 17: 819-829.
73. Ragheb, S., R. Lisak, R. Lewis, et al. 2008. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch. Neurol. 65: 1358-1362.
74. Kim, J.Y., Y. Yang, J.S. Moon, et al. 2008. Serum BAFF expression in patients with myasthenia gravis. J. Neuroimmunol. 199: 151-154.
75. Scuderi, F., P.E. Alboini, E. Bartoccioni & A. Evoli. 2011. BAFF serum levels in myasthenia gravis: effects of therapy. J. Neurol. 258: 2284-2285.
76. Li, X., B.G. Xiao, J.Y. Xi, et al. 2008. Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis. Clin. Immunol. 126: 180-188.
77. Thangarajh, M., L. Kisiswa, R. Pirskanen & J. Hillert. 2007. The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis. Scand. J. Immunol. 65: 461-466.
78. Thangarajh, M., T. Masterman, L. Helgeland, et al. 2006. The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis. J. Neuroimmunol. 178: 161-166.
79. Meraouna, A., G. Cizeron-Clairac, R.L. Panse, et al. 2006. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108: 432-440.
80. Shiao, Y.M., C.C. Lee, Y.H. Hsu, et al. 2010. Ectopic and high CXCL13 chemokine expression in myasthenia gravis with thymic lymphoid hyperplasia. J. Neuroimmunol. 221: 101-106.
81. Aloisi, F. & R. Pujol-Borrell. 2006. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6: 205-217.
82. Gommerman, J.L. & J.L. Browning. 2003. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat. Rev. Immunol. 3: 642-655.
83. McCarthy, D.D., L. Summers-Deluca, F. Vu, et al. 2006. The lymphotoxin pathway: beyond lymph node development. Immunol. Res. 35: 41-54.
84. Ruddle, N.H. 1999. Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development. Immunol. Res. 19: 119-125.
85. Sutherland, A.P., L.G. Ng, C.A. Fletcher, et al. 2005. BAFF augments certain Th1-associated inflammatory responses. J. Immunol. 174: 5537-5544.
86. Lai Kwan Lam, Q., O. King Hung Ko, B.J. Zheng & L. Lu. 2008. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc. Natl. Acad. Sci. USA 105: 14993-14998.
87. Huard, B., P. Schneider, D. Mauri, et al. 2001. T cell costimulation by the TNF ligand BAFF. J. Immunol. 167: 6225-6231.
88. Baker, K.P., B.M. Edwards, S.H. Main, et al. 2003. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48: 3253-3265.
89. Espinosa, G. & R. Cervera. 2010. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Drugs Today 46: 891-899.
90. Navarra, S.V., R.M. Guzman, A.E. Gallacher, et al. 2011. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377: 721-731.
91. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. 1999. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53: 457-465.
92. Schwid, S.R. & J.H. Noseworthy. 1999. Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss. Neurology 53: 444-445.
93. van Oosten, B.W., F. Barkhof, L. Truyen, et al. 1996. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531-1534.
94. Enayati, P.J. & K.A. Papadakis. 2005. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J. Clin. Gastroenterol. 39: 303-306.
95. Robinson, W.H., M.C. Genovese & L.W. Moreland. 2001. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis Arthritis Rheum. 44: 1977-1983.
96. Chung, J.H., G.P. Van Stavern, L.P. Frohman & R.E. Turbin. 2006. Adalimumab-associated optic neuritis. J. Neurol. Sci. 244: 133-136.
97. Stubgen, J.P. 2008. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 37: 281-292.
98. Richez, C., P. Blanco, A. Lagueny, et al. 2005. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 64: 1468-1470.
99. Lin, W.Y., Q. Gong, D. Seshasayee, et al. 2007. Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood 110: 3959-3967.
100. Carbonatto, M., P. Yu, M. Bertolino, et al. 2008. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci. 105: 200-210.
101. Dall'Era, M., E. Chakravarty, D. Wallace, et al. 2007. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 56: 4142-4150.
102. Tak, P.P., R.M. Thurlings, C. Rossier, et al. 2008. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 58: 61-72.
103. Hartung, H.-P. & B. Kieseier. 2010. Atacicept: targeting B cells in multiple sclerosis. Ther. Adv. Neurol. Disord. 3: 205-216.
104. Baek, W.S., A. Bashey & G.L. Sheean. 2007. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J. Neurol. Neurosurg. Psychiatr. 78: 771.
105. Blum, S., D. Gillis, H. Brown, et al. 2011. Use and monitoring of low dose rituximab in myasthenia gravis. J. Neurol. Neurosurg. Psychiatr. 82: 659-663.
106. Burusnukul, P., T.D. Brennan & E.J. Cupler. 2010. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase +myasthenia gravis. J. Clin. Neuromuscul. Dis. 12: 85-87.
107. Hain, B., K. Jordan, M. Deschauer & S. Zierz. 2006. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 33: 575-580.
108. Lindberg, C. & M. Bokarewa. 2010. Rituximab for severe myasthenia gravis-experience from five patients. Acta. Neurol. Scand. 122: 225-228.
109. Maddison, P., J McConville, M.E. Farrugia, et al. 2011. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatr. 82: 671-673.
110. Nowak, R.J., D.B. Dicapua, N. Zebardast & J.M. Goldstein. 2011. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther. Adv. Neurol. Disord. 4: 259-266.
111. Stein, B. & S.J. Bird. 2011. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis. J. Clin. Neuromuscul. Dis. 12: 163-164.
112. Stieglbauer, K., R. Topakian, V. Schaffer & F.T. Aichner. 2009. Rituximab for myasthenia gravis: three case reports and review of the literature. J. Neurol. Sci. 280: 120-122.
113. Thakre, M., J. Inshasi & M. Marashi. 2007. Rituximab in refractory MuSK antibody myasthenia gravis. J. Neurol. 254: 968-969.
114. Wylam, M.E., P.M. Anderson, N.L. Kuntz & V. Rodriguez. 2003. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J. Pediatr. 143: 674-677.
115. Zaja, F., D. Russo, G. Fuga, et al. 2000. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55: 1062-1063.
116. Zebardast, N., H.S. Patwa, S.P. Novella & J.M. Goldstein. 2010. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 41: 375-378.
117. Lavie, F., C. Miceli-Richard, M. Ittah, et al. 2007. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66: 700-703.
118. Pers, J.O., V. Devauchelle, C. Daridon, et al. 2007. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum. 56: 1464-1477.
119. Pranzatelli, M.R., E.D. Tate, A.L. Travelstead & S.J. Verhulst. 2011. Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS. Cytokine 53: 384-389.
120. Vallerskog, T., M. Heimburger, I. Gunnarsson, et al. 2006. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 8: R167.
121. Leite, M.I., S. Jacob, S. Viegas, et al. 2008. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131: 1940-1952.
122. Zen, M., M. Canova, C. Campana, et al. 2011. The kaleidoscope of glucorticoid effects on immune system. Autoimmun. Rev. 10: 305-310.
123. Le Pottier, L., B. Bendaoud, M. Dueymes, et al. 2007. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J. Clin. Immunol. 27: 257-265.